Daily Cosmetic Research Analysis
A prospective IMPT cohort in nasopharyngeal carcinoma links mean oral cavity and pharyngeal constrictor doses to clinically meaningful, patient-reported dysphagia and proposes actionable dose thresholds. Advances in dermal delivery include a curcumin bigel that enhances skin deposition and in vitro wound closure, while a broad review highlights AI- and phage display-enabled peptide innovations with implications for cosmetics and biotechnology.
Summary
A prospective IMPT cohort in nasopharyngeal carcinoma links mean oral cavity and pharyngeal constrictor doses to clinically meaningful, patient-reported dysphagia and proposes actionable dose thresholds. Advances in dermal delivery include a curcumin bigel that enhances skin deposition and in vitro wound closure, while a broad review highlights AI- and phage display-enabled peptide innovations with implications for cosmetics and biotechnology.
Research Themes
- Patient-reported outcomes and dose constraints in proton therapy
- Dermal delivery systems and cosmeceutical formulation
- AI- and phage display-enabled peptide innovation
Selected Articles
1. Prospective longitudinal study of patient-reported dysphagia in nasopharyngeal carcinoma treated with intensity-modulated proton therapy.
In a prospective NPC cohort treated with IMPT, 69% experienced a clinically significant MDADI decline and 34% failed to recover by 12 months. Higher mean doses to the oral cavity, S-PCM, and M-PCM independently predicted worse patient-reported dysphagia, and specific dose constraints (oral cavity <12.2 Gy[RBE], S-PCM <55.4 Gy[RBE], M-PCM <36.1 Gy[RBE]) were associated with substantial risk reduction.
Impact: Provides actionable, patient-reported outcome–driven dose constraints for IMPT planning in NPC, linking specific mean doses to dysphagia risks.
Clinical Implications: Incorporate mean dose constraints for the oral cavity and pharyngeal constrictors during IMPT optimization to mitigate dysphagia, and use longitudinal PROs to counsel patients and guide survivorship care.
Key Findings
- Clinically significant MDADI decline (≥10 points) occurred in 69%; no recovery to baseline at 12 months in 34%.
- Higher mean doses to the oral cavity and S-PCM predicted CSD (OR 1.210 and 1.249, respectively).
- Oral cavity <12.2 Gy[RBE] and S-PCM <55.4 Gy[RBE] associated with CSD risk <0.6; M-PCM <36.1 Gy[RBE] associated with NRB risk <0.2.
Methodological Strengths
- Prospective longitudinal design with seven PRO time points (baseline to 12 months).
- Multivariable modeling of clinical, sociodemographic, and dosimetric predictors.
Limitations
- Single-institution cohort with modest sample size and incomplete PRO completion (49/58).
- Follow-up limited to 12 months; no objective swallow physiology tests reported.
Future Directions: Validate dose thresholds in multicenter cohorts with longer follow-up and integrate constraints into IMPT planning algorithms and prospective trials.
PURPOSE: To evaluate longitudinal changes in patient-reported dysphagia and identify its predictors in nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated proton therapy (IMPT). METHODS: Newly diagnosed, non-metastatic NPC patients were prospectively enrolled. The MD Anderson Dysphagia Inventory (MDADI) was administered at seven time points from baseline to 12 months post-IMPT. Primary endpoints included: (1) clinically significant decline (CSD), defined as a ≥10-point decrease in MDADI composite score from baseline to end of IMPT, and (2) no recovery to baseline (NRB) at 12 months. Clinical, sociodemographic, and dosimetric variables were analyzed. RESULTS: Of 58 patients, 49 completed MDADI assessments at all time-points. CSD occurred in 69 %, and NRB in 34 %. Patients with CSD had significantly higher mean doses to the oral cavity and superior pharyngeal constrictor muscle (S-PCM) (p < 0.05), while those with NRB had higher doses to the oral cavity, S-PCM, and middle PCM (M-PCM) (p < 0.01). After adjustment clinical and sociodemographic variables, independent predictors of CSD were mean dose to oral cavity (OR = 1.210) and S-PCM (OR = 1.249). Predictors of NRB included mean dose to oral cavity (OR = 1.268), S-PCM (OR = 1.211), and M-PCM (OR = 1.166). Limiting mean doses below 12.2Gy[RBE] (oral cavity) and 55.4Gy[RBE] (S-PCM) reduced CSD risk to <0.6 and NRB risk to <0.2, respectively; a dose below 36.1 Gy[RBE] (M-PCM) reduced NRB risk to <0.2. CONCLUSION: Minimizing mean doses to the oral cavity, S-PCM, and M-PCM is crucial for reducing patient-reported dysphagia following IMPT in NPC patients.
2. Formulation Development and Characterization of Bigels Containing Curcumin for Topical Skin Delivery.
Curcumin bigels combining hydrogel and organogel phases were optimized, with BG30 (HG:OG 70:30) yielding the highest skin deposition and superior in vitro wound closure. All bigels exhibited favorable rheology and low oil leaching, and were non-cytotoxic across tested curcumin concentrations.
Impact: Addresses curcumin’s long-standing skin penetration limitation by leveraging bigel architecture and identifies a formulation (BG30) with clear advantages in deposition and wound-healing assays.
Clinical Implications: Supports development of cosmeceutical and therapeutic topical curcumin products targeting inflammation, wound care, and skin aging, pending in vivo validation.
Key Findings
- BG30 (HG:OG 70:30) achieved the highest curcumin accumulation in stratum corneum and viable epidermis/dermis (1.61±0.17× and 3.63±0.89× vs. OG control).
- All bigels were o/w systems with microdroplets (7.10–30.60 μm), showed pseudoplastic rheology, and low oil leaching.
- Non-cytotoxic to L929 cells at 62.5–1,000 μg/mL; BG30 yielded 70.11±1.11% migration at 24 h and 100% at 48 h in scratch assay.
Methodological Strengths
- Systematic formulation screening across multiple HG:OG ratios with physicochemical and rheological characterization.
- Integrated ex vivo skin permeation, cytotoxicity, and cell migration assays with appropriate controls.
Limitations
- Evidence limited to in vitro/ex vivo assays; no in vivo animal or human data.
- Single active concentration (0.25% curcumin) tested within OG; stability and long-term safety not assessed.
Future Directions: Conduct in vivo efficacy and safety studies, assess long-term stability and scalability, and compare against state-of-the-art dermal delivery systems.
Curcumin, a pleiotropic molecule, has been reported to modulate skin health and functions owing to its anti-inflammation, wound healing, antimicrobial, and anti-aging effects. Curcumin, a lipophilic molecule, exhibits poor skin penetration that results in decreased efficacy in treating skin diseases. In this study, a bigel containing curcumin was formulated to enhance skin deposition of curcumin. Generally, bigels are composed of hydrogel (HG) and organogel (OG) and feature the ideal characteristics of both systems. The HG contained HPMC 2% w/v, and the OG contained Span® 60, almond oil, and curcumin (0.25%) mixed in different HG:OG proportions from 90:10 to 10:90. Three ratios of HG:OG, BG50 (50:50), BG40 (60:40), and BG30 (70:30) successfully formed yellowish turbid smooth bigels. The bigels were characterized as an o/w system with microdroplet size (7.10-30.60 µm) under a microscope. All bigel formulations showed pseudoplastic behavior and had low oil leaching. Skin permeation experiments revealed that BG30 provided the highest curcumin accumulation in the stratum corneum, and viable epidermis and dermis, which was higher than the control OG for 1.61 ± 0.17 and 3.63 ± 0.89-fold, respectively. All bigels were nontoxic on the murine fibroblast cell line L929 at 62.5-1,000 μg/mL of curcumin. B30 provided the highest wound healing effect as determined by the L929 scratch assay. The % migration increased to 70.11 ± 1.11 at 24 h and to 100% at 48 h. These findings suggest that BG30 could be potentially used to deliver curcumin intended for topical applications.
3. From precision synthesis to cross-industry applications: The future of emerging peptide technologies.
This narrative review synthesizes advances in peptide discovery and optimization, emphasizing phage display and AI to accelerate identification and engineering. It outlines medical, food, and cosmetic applications and highlights nanocarriers as key enablers for stability and delivery.
Impact: Offers a cross-industry, technology-forward roadmap that connects discovery platforms with translational applications, informing strategic R&D in cosmetics and biomedicine.
Clinical Implications: Guides selection and design of peptide actives and delivery systems for dermatologic and cosmetic products (e.g., collagen-stimulating peptides) and informs translational paths for therapeutic peptides.
Key Findings
- Phage display and AI integration accelerates peptide identification and structural optimization.
- Peptides have broad applications spanning medicine (including AMPs), functional foods, and cosmetics (collagen stimulation, regeneration, anti-aging).
- Emerging nanocarriers improve peptide stability, absorption, and half-life for effective delivery.
Methodological Strengths
- Comprehensive, cross-disciplinary synthesis linking discovery platforms to applications.
- Highlights enabling technologies (AI, phage display, nanocarriers) with mechanistic rationale.
Limitations
- Narrative (non-systematic) review without PRISMA methodology; potential selection bias.
- Lacks quantitative meta-analytic synthesis and standardized critical appraisal.
Future Directions: Develop standardized evaluation frameworks for cosmetic/therapeutic peptides, advance scalable GMP manufacturing, and clinically validate nanocarrier-enabled delivery.
Peptides, derived primarily from natural bioactive sources, play essential roles in human physiological processes such as hormone regulation and nerve signal transmission. Recent advances in phage display technology have revolutionized peptide screening, enabling the rapid and efficient identification of billions of peptide within a single day. The integration of artificial intelligence (AI) has further accelerated peptide discovery, allowing for the swift identification of bioactive sequences and structural optimization to enhance their stability, efficacy, and target specificity. Peptides have demonstrated extensive applications across diverse industries. In medicine, they exhibit potent antibacterial, antiviral, and antitumor properties, with antimicrobial peptides (AMPs) emerging as promising alternatives against multidrug-resistant bacteria. In the food industry, peptides contribute to functional foods by providing antihypertensive, antioxidant, and immunomodulatory effects, promoting overall health. The cosmetics sector also relies on peptides for their ability to stimulate collagen production, enhance skin regeneration, and deliver anti-aging benefits, making them key ingredients in advanced skincare formulations. Emerging delivery nanocarrier systems, aim to improve peptide stability, absorption, and half-life. With ongoing technological breakthroughs and interdisciplinary collaboration, peptides are poised to play an increasingly pivotal role in modern medicine and biotechnology, offering innovative solutions for a range of health, food, and cosmetic applications.